Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)
A phase 1/2 trial of Carboplatin, Paclitaxel / nab-paclitaxel in ovarian cancer, run by Imunon, active and no longer recruiting.
Overview
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) is a phase 1/2 interventional study registered as NCT03393884 by Imunon, with 130 participants planned, started 2018-09-05 and due to reach its primary completion in 2024-07-25. Interventions recorded: IMNN-001, Carboplatin, Paclitaxel. Conditions listed: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Shares Imunon, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialPhase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat
Shares Imunon, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialCATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialStudy to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialA Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialOregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
- TrialA Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
- TrialOregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.